Skip to main content
    E

    Ernexa Therapeutics Inc. (ERNA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.63
    -0.06 (-3.55%)

    Market Cap: $2.86M

    Last updated: Nov 17, 2026 at 4:10 PM ET

    Ernexa Therapeutics Inc. (ERNA) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Ernexa Therapeutics (ERNA) has a market cap of $2.86M. It holds $5.58M more cash than debt, 194.90% of its market cap. Revenue fell 100.00% over the last 12 months from the 12 months before.

    Total Valuation

    Market Cap$2.86M
    Latest price (Nov 17, 2026)$1.63

    Key Dates

    The next earnings report is expected on Mar 11, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 11, 2027 (expected)
    Last Earnings DateNov 6, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 31.87% in the quarter ended Sep 30, 2026.

    Shares Outstanding1.56M
    Shares Change (QoQ)+31.87%

    Price Statistics

    The stock is down 95.71% over 52 weeks and trades 38.26% below its 50-day average.

    Beta (1Y)0.75
    52-Week Change-95.71%
    1-Month Change-17.68%
    3-Month Change-63.21%
    6-Month Change-85.76%
    5-Year Change-100.00%
    10-Year Change-100.00%
    Total Return (1Y)-95.71%
    Total Return (3Y CAGR)-84.32%
    Total Return (5Y CAGR)-87.38%
    Return vs SPY (1Y)-107.15%
    Max Drawdown (1Y)-95.68%
    Max Drawdown (3Y)-99.82%
    Sharpe Ratio (1Y)-2.13
    Correlation with SPY (1Y)0.07
    50-Day Average$2.64
    200-Day Average$5.65
    52-Week Range$1.67 to $37.50
    RSI (14 Days)30.3
    Average Volume (20 Days)14.79K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 2.57x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio2.57x
    Quick Ratio2.57x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -320.82% and return on assets is -196.49% over the last 12 months.

    Return on Equity (ROE)-320.82%
    Return on Assets (ROA)-196.49%

    Scores

    ERNA has a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was $0 over the last 12 months.

    Revenue$0
    Revenue Growth (YoY)-100.00%
    Gross Profit-$69.00K
    Operating Income-$14.78M
    Pretax Income-$14.06M
    Net Income-$13.96M
    EBITDA-$14.05M
    Reported EPS (TTM)-$17.05

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 61.27% of the $7.10M in total assets.

    Cash and Equivalents$5.58M
    Total Debt$0
    Net Cash$5.58M
    Net Cash Per Share$3.57
    Working Capital$4.11M
    Shareholder Equity$4.35M
    Book Value Per Share$2.79
    Total Assets$7.10M
    Total Liabilities$2.75M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$10.73M
    FCF Per Share-$6.59
    Depreciation and Amortization$245.00K

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Dividends and Yields

    ERNA does not pay a dividend.

    Buyback Yield-558.48%
    Shareholder Yield-558.48%

    Stock Splits

    The last split was a 1-for-25 reverse split on May 4, 2026.

    Last Split DateMay 4, 2026
    Split TypeReverse split
    Split Ratio1:25

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About ERNA

    What is ERNA's market cap?

    Ernexa Therapeutics has a market cap of $2.86M.

    How many shares of ERNA are outstanding?

    Ernexa Therapeutics has 1.56M shares outstanding.

    Does ERNA pay a dividend?

    No. Ernexa Therapeutics does not pay a dividend.

    How much debt does ERNA have?

    Ernexa Therapeutics has $0 of total debt and $5.58M of cash and equivalents, a net cash position of $5.58M.